Publications
56
Citations
847
Est. group size
~11
Recurring co-author estimate
Active years
39
Publishing since 1988
Debra G. Wheeler's research focuses on developing and testing drugs that block von Willebrand Factor (VWF), a blood protein involved in clot formation, as a way to treat and prevent strokes caused by blood vessel blockages. Much of the work involves preclinical testing in mouse, canine, and human blood models of stroke and blood clot conditions, alongside early clinical trials of a VWF-blocking compound (BB-031) in humans. The research bridges laboratory drug development with translational studies aimed at improving stroke treatment beyond current clot-dissolving therapies.
Publication output has been variable but fairly steady over the past decade, with recurring peaks (e.g., 2017-2018, 2022) and a dip in 2021, averaging just over 3 papers per year in the last 5 years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abstract DP316: BB-031 inhibition of VWF in AIS: does it cast a large NETs?
Stroke · 2026
- Von Willebrand factor targeted thrombolysis in canine basilar artery occlusion
Frontiers in Neurology · 2024
- 102 BB-031 Recanalizes MCAO and Reduces Inflammation in Canine Model of LVO Stroke
Neurosurgery · 2024
- Abstract 4116141: Von Willebrand Factor Inhibition by BB-031 Prevents and Thrombolyses Clots in a Murine Model of Venous Thrombosis
Circulation · 2024
- A canine thromboembolic model of anterior circulation large vessel occlusion stroke
Heliyon · 2023
- Abstract 94: Randomized, Double-blind, Placebo-controlled Phase 1 Study Of Vwf-binding Aptamer, Bb-031: Safety, Tolerability, Pharmacokinetic And Pharmacodynamic Activity In Healthy Volunteers
Stroke · 2023
- Abstract TMP4: BB-031 Reduces Platelet Reactivity And Attenuates Von Willebrand Factor Levels In A Large Vessel Occlusion Stroke Model
Stroke · 2023
- Abstract 45: Vwf Inhibitor Lyses Middle Cerebral Artery Occlusion After 6 Hours Of Large Vessel Occlusion Stroke
Stroke · 2022
- Abstract TP243: Treatment With Vwf Inhibitor Dtri-031 In Combination With Rtpa Increases Thrombolytic Efficacy Compared To Rtpa Or Aspirin In Mouse, Canine, And Human Blood
Stroke · 2022
- 167 Reversible VWF Inhibitor Lyses MCA Occlusion 6 Hours after Large Vessel Occlusion Stroke
Neurosurgery · 2022
- A Canine Thromboembolic Model of Anterior Circulation Large Vessel Occlusion Stroke
SSRN Electronic Journal · 2022
- PERK Inhibition Mitigates Restenosis and Thrombosis
JACC Basic to Translational Science · 2020
- Quantification of Cerebral Perfusion using Laser Speckle Imaging and Infarct Volume using MRI in a Pre-clinical Model of Posterior Circulation Stroke
Journal of Visualized Experiments · 2020
- Abstract WP99: Reversible VWF Inhibitor Reduces Stroke Volumes Compared to TPA in Canine Model of Large Vessel Occlusion Stroke
Stroke · 2020
- Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels
Molecular Therapy · 2019
- Stroke×10
- Arteriosclerosis Thrombosis and Vascular Biology×4
- Journal of Visualized Experiments×3
- Circulation×2
- Neurosurgery×2
- Matthew Joseph
Medicine · The Ohio State University
- Allyson Huttinger
Medicine · The Ohio State University
- Cassandra Forrest
Medicine · The Ohio State University
- Deepak Gulati
Medicine · The Ohio State University
- Eric Kontowicz
Medicine · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile